Literature DB >> 1672261

Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma.

C Boutin1, J R Viallat, N Van Zandwijk, J T Douillard, J C Paillard, J C Guerin, P Mignot, J Migueres, F Varlet, A Jehan.   

Abstract

Twenty-two consecutive patients with malignant diffuse pleural mesothelioma were treated with recombinant gamma-interferon by the intrapleural route. Diagnosis was made by thoracoscopic examination and all cases were confirmed by the French Mesothelioma Panel of Pathologist. Patients were staged based on thoracoscopic examination and computed tomography (CT) scan: 12 patients were classified as Stage I and 10 were Stage II. A solution of gamma-interferon (40 X 106 U) was infused twice a week over 2 months. Every patient experienced fever. One patient had a Grade 2 leukopenia and one patient suffered from pleural empyema. Response evaluation was based on the following: (1) CT scan performed 2 weeks after treatment ended, and (2) repeat thoracoscopic examination with histopathologic verification in nine patients who had demonstrated a stabilization or a regression of the disease on CT scan. From the original group, 19 patients could be evaluated. Four complete thoracoscopic histopathologic responses and one partial response were observed in Stage I patients (56%). One partial response was observed in Stage II patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1672261     DOI: 10.1002/1097-0142(19910415)67:8<2033::aid-cncr2820670804>3.0.co;2-8

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

1.  Cytokines and cancer.

Authors:  S Malik; J Waxman
Journal:  BMJ       Date:  1992-08-01

Review 2.  Diagnosis, staging, and surgical treatment of malignant pleural mesothelioma.

Authors:  Michael Kent; David Rice; Raja Flores
Journal:  Curr Treat Options Oncol       Date:  2008-08-29

3.  Laparoscopy: an important tool in the staging of malignant pleural mesothelioma.

Authors:  K C Conlon; V W Rusch; S Gillern
Journal:  Ann Surg Oncol       Date:  1996-09       Impact factor: 5.344

Review 4.  Local and systemic therapies for malignant pleural mesothelioma.

Authors:  Daniel Gomez; Anne S Tsao
Journal:  Curr Treat Options Oncol       Date:  2014-12

Review 5.  The role of intracavitary therapies in the treatment of malignant pleural mesothelioma.

Authors:  Pietro Bertoglio; Vittorio Aprile; Marcello Carlo Ambrogi; Alfredo Mussi; Marco Lucchi
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

6.  Treatment of a patient with malignant mesothelioma with interferon-alpha 2 based on in vitro sensitivity tests.

Authors:  V Sexl; L Wagner; M Wiesholzer; E Presterl; W Base
Journal:  Clin Investig       Date:  1994-03

Review 7.  Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies.

Authors:  Andrew R Haas; Daniel H Sterman
Journal:  Clin Chest Med       Date:  2013-01-17       Impact factor: 2.878

Review 8.  Closing faucets: the role of anti-angiogenic therapies in malignant pleural diseases.

Authors:  D Marquez-Medina; S Popat
Journal:  Clin Transl Oncol       Date:  2015-12-17       Impact factor: 3.405

9.  Successful immunochemotherapy for patients with malignant mesothelioma: report of two cases.

Authors:  M Tani; H Tanimura; H Yamaue; S Mizobata; M Yamamoto; M Iwahashi; K Ura; Y Nagai; T Tsunoda; H Wakasaki; K Nanjo; K Fujino; S Yukawa
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

Review 10.  Photodynamic therapy for mesothelioma.

Authors:  S M Hahn; R P Smith; J Friedberg
Journal:  Curr Treat Options Oncol       Date:  2001-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.